Top Ten most popular articles on Pharmafile.com this week
pharmafile | February 21, 2020 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Drug market, Europe, coronavirus, opioid crisis, opioids
The coronavirus is again in the news, with the Indian government considering banning exports of medicine as the epidemic threatens vital pharmaceutical supplies from China. This is not just a regional issue, as Europe and the US are also having their drug production pipeline disrupted by the epidemic.
In UK news, NICE gives initial ‘no’ to NHS England for kidney cancer drug, while experts have called on the organisation to ban the sale of over the counter codeine.
10. Global drug market’s production line threatened by coronavirus
The global drug market is facing issues over production due to the coronavirus ravaging the supply line from China.
The European Commission (EC) has awarded marketing approval to Pfizer’s Vyndaqel (tafamidis), it has emerged, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult cardiomyopathy patients (ATTR-CM).
8. Experts call on NICE to recommended a ban on OTC codeine sales
Experts have called for a ban on the sale of over the counter codeine as NICE is set to publish its draft guidance for the management of chronic pain next week.
The European Commission (EC) has chosen to approve Novartis’ Beovu (brolucizumab) injection, it has emerged, as a treatment for wet age-related macular degeneration (AMD).
6. Janssen shows off Phase 3b interim data for Stelara in Crohn’s disease
Janssen has revealed new interim Phase 3b data from a study investigating the efficacy of Stelara (ustekinumab) in the treatment of moderate to severe Crohn’s disease (CD).
5. CEO of PixarBio Corporation sentenced to prison for defrauding investors
Frank Reynolds, the CEO of Boston based PixarBio Corporation, was sentenced to seven years in prison for defrauding investors and obstructing a federal investigation.
4. GlaxoSmithKline acquires two solid tumor cell therapies from Immatics for $50 million
GlaxoSmithKline has struck a deal to access two Immatics T-cell receptor (TCR) therapeutics.
3. Strong Phase 3 data for Takeda’s subcutaneous Entyvio in moderate to severe Crohn’s disease
Takeda has shared positive new Phase 3 data on a subcutaneous formulation of its gut-selective biologic Entyvio (vedolizumab) as a maintenance therapy for moderately to severely active Crohn’s disease (CD) in adult patients.
2. India considering export restrictions on antibiotics due to coronavirus
The Indian government is considering an export ban on antibiotics, vitamins and hormones due to the lockdown of Hubei province, the epicenter of the coronavirus and a major supplier of materials for pharmaceutical ingredients.
1. NICE gives initial ‘no’ to NHS England for kidney cancer drug
The National Institute for Health and Care Excellence (NICE) has not recommended Keytruda (pembrolizumab) and Inlyta (axitinib) for the treatment of advanced renal cell cancer.
Related Content
FDA accepts new drug application for Orexo’s opioid overdose medication
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for …
FDA approves a second OTC naloxone nasal spray
The US Food and Drug Administration (FDA) has announced that it has approved RiVive, 3mg …
FDA approves prescription nasal spray for opioid overdose treatment
The US Food and Drug Administration (FDA) has announced that it has approved Opvee, the …
